Page last updated: 2024-08-22

camptothecin and rubitecan

camptothecin has been researched along with rubitecan in 141 studies

Research

Studies (141)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.71)	18.7374
1990's	31 (21.99)	18.2507
2000's	87 (61.70)	29.6817
2010's	18 (12.77)	24.3611
2020's	4 (2.84)	2.80

Authors

Authors	Studies
Nicholas, AW; Wall, ME; Wani, MC	1
Cao, Z; Giovanella, B; Harris, N; Kozielski, A; Stehlin, JS; Vardeman, D	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Bermejo, M; Corma, A; Díaz Cabañas, MJ; García-Giménez, JL; Gonzalez-Alvarez, I; Gonzalez-Alvarez, M; Mangas-Sanjuán, V; Rodríguez-Berna, G	1
Khaoustov, VI; Krishnan, B; Mearns, M; Noda, A; Ozer, A; Slagle, BL; Smith, JR; Yoffe, B	1
Giovanella, B; Harris, N; Mendoza, J; Pantazis, P	2
DeJesus, A; Early, J; Giovanella, B; Kozielski, A; Mendoza, J; Pantazis, P; Vardeman, D	1
DeJesus, A; Giovanella, BC; Kufe, D; Mendoza, JT; Pantazis, P; Rubin, E	1
DeJesus, A; Early, J; Giovanella, BC; Mendoza, J; Pantazis, P; Shaw, M	1
Giovanella, BC; Harris, NJ; Hinz, HR; Natelson, EA	1
Bharti, A; Giovanella, B; Kufe, D; Pantazis, P; Rubin, E; Toppmeyer, D	1
DeJesus, AR; Early, JA; Giovanella, BC; Mendoza, JT; Pantazis, P	1
Giovanella, BC	1
Early, JA; Giovanella, BC; Kozielski, AJ; Mendoza, JT; Natelson, EA; Pantazis, P	1
Early, JA; Giovanella, BC; Hinz, HR; Kozielski, AJ; Mendoza, JT; Pantazis, P	2
Chatterjee, D; Pantazis, P; Wyche, JH	1
De Ipolyi, PD; Fehir, KM; Giovanella, BC; Harris, N; Natelson, EA; Stehlin, JS; Verschraegen, CF	1
Gupta, E; Ibrahim, N; Li, XG; Mendoza, J; Pantazis, P; Patel, M; Rubin, EH; Saleem, A	1
Chatterjee, D; DeJesus, A; Early, J; Giovanella, B; Pantazis, P; Plaschke, S; Wyche, J	1
Ahmed, AE; Giovanella, BC; Jacob, S; Kozielski, AJ; Liehr, JG; Stehlin, JS	1
Epstein, JS; Moulton, S; Pantazis, P; Sadaie, MR	1
Edwards, CL; Ende, K; Freedman, RS; Giovanella, BC; Kavanagh, JJ; Kudelka, AP; Natelson, EA; Stehlin, JS; Verschraegen, CF	1
DeJesus, A; Early, J; Giovanella, B; Pantazis, P	1
Aggarwal, BB; Mendoza, J; Pantazis, P; Raju, U; Singh, S	1
Bigg, DC; Lavergne, O	1
Doniger, J; Hung, CL; Pantazis, P; Sadaie, MR	1
Coil, D; Davis, B; De Ipolyi, PD; Giovanella, BC; Natelson, EA; Stehlin, JS; Trojacek, A; Wallace, P; Wolk, D	1
Cao, Z; Chatterjee, D; Han, Z; Pantazis, P; Wyche, J	1
Chatterjee, D; Han, Z; Pantazis, P; Wyche, J	2
Edwards, CL; Freedman, RS; Giovanella, BC; Gupta, E; Harris, N; Kavanagh, JJ; Kudelka, AP; Loyer, E; Steger, M; Stehlin, JS; Steltz, V; Verschraegen, CF	1
Gilbert, BE; Giovanella, BC; Knight, V; Koshkina, NV; Waldrep, JC	1
Amorino, GP; Choy, H; Hercules, SK; Mohr, PJ; Pyo, H	1
Karaberis, E; Mourelatos, D	1
Gilbert, B; Giovanella, BC; Kleinerman, E; Knight, V; Koshkina, N; Waldrep, C	1
Gilbert, BE; Jia, SF; Kleinerman, ES; Knight, V; Koshkina, NV; Waidrep, C; Worth, LL	1
Gilbert, BE; Giovanella, BC; Kleinerman, ES; Knight, V; Koshkina, NV; Waldrep, JC	1
Chow, DS; Giovanella, BC; Gong, L; Wolfe, MD	1
Ahmed, AE; Giovanella, BC; Harris, NJ; Liehr, JG; Mendoza, J	1
Gilbert, BE; Giovanella, B; Jaeckle, K; Knight, V; Verschraegen, CF	1
Bernacki, RJ; Brun, Y; Gambacorta, P; Greco, WR; Pera, P	1
Giovanella, B; Kemp, KR; Liehr, JG	1
Abbruzzese, JL; Kavanagh, JJ; Kudelka, AP; Loyer, E; Rubin, E; Siegler, D; Verschraegen, CF; Vincent, M	1
Campbell, K; Gilbert, BE; Harris, N; Huaringa, AJ; Keus, L; Knight, V; Leyva, FJ; Nelson-Taylor, T; Newman, R; Verschraegen, CF	1
Brady, JN; Doniger, J; Hung, CL; Palini, A; Pantazis, P; Radonovich, MF; Sadaie, MR; Snyder, SW	1
Chatterjee, D; Kirchhoff, S; Krammer, PH; Krueger, A; Pantazis, P; Peter, ME; Schmitz, I; Wyche, JH; Yeung, K	1
Giovanella, BC; Harris, NJ; Hinz, HR; Kozielski, AJ; Stehlin, JS; Vardeman, DM	1
Antonakis, PT; Golematis, BX; Konstadoulakis, MM; Manouras, AP; Mylonaki, DB; Stathopoulos, GP; Tsibloulis, BG	1
Amorino, GP; Cao, Q; Choy, H; Kim, JS; Pyo, H	1
Bedikian, AY; Ellerhorst, JA; Eton, O; Papadopoulos, NE; Plager, C; Smith, TM	1
Adank, S; Beijnen, JH; Botma, HJ; Ganser, A; Herr, A; Rosing, H; Schöffski, P; Van den Brande, J; Vermorken, JB; Volk, J; Wanders, J	1
Densmore, CL; Gautam, A; Gilbert, B; Knight, V; Koshkina, N; Melton, S; Roberts, L; Waldrep, JC	1
Campone, M; Chollet, P; Fety-Deporte, R; Fumoleau, P; Lacombe, D; Lesimple, T; Menten, J; Paoletti, X; Raymond, E; Stupp, R	1
Potter, DM	1
Beijnen, JH; Jansen, S; Rizzo, J; Rosing, H; Schellens, JH; Schoemaker, NE; Schöffski, P	1
Brayton, C; Gilbert, BE; Knight, V; Seryshev, A	1
Chen, SF; Hollister, B; Mishra, A; Sands, H; Stoeckler, JD	1
Bearss, D; Von Hoff, DD	1
Arquette, MA; Denes, A; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Mutch, DG; Picus, J; Rader, JS; Sun, SL; Tan, BR	1
Beijnen, JH; Mathôt, RA; Rosing, H; Schellens, JH; Schoemaker, NE; Schöffski, P	1
Clark, JW; Fuchs, CS; Garcia-Carbonero, R; Michaelson, MD; Paul Eder, J; Ryan, DP; Supko, JG	1
Cao, ZS; Early, J; Giovanella, B; Harris, N; Kozielski, A; Mendoza, J; Pantazis, P	1
Du, Y; Li, K; Xu, JH; Zhang, YF; Zhong, DF	1
Chen, X; Li, K; Li, Y; Zhong, D	1
Beach, J; Benjamin, RS; Burgess, MA; Jenkins, J; Papadopoulos, N; Patel, SR; Trent, J	1
Li, K; Zhong, DF	1
Bailly, C; Lansiaux, A	1
Bates, SE; Gounder, MK; Rajendra, R; Ross, DD; Rubin, EH; Saleem, A; Schellens, JH; Sinko, P	1
Balan, KV; Han, Z; Hu, X; Pantazis, P; Ramos-DeSimone, N; Wyche, JH	1
Burke, TG; Latus, LJ; Zhang, J	1
Kulke, MH	1
Charles-Williams, S; Gounder, MK; Gu, Z; Lin, Y; Rajendra, R; Roychowdhury, M; Rubin, EH; Sands, H; Shih, WJ; Sun, SL	1
Doniger, J; Mayner, R; Sadaie, MR	1
Guiney, P; Haney, LG; Lenaz, L; Miller, KD; Murry, DJ; Sledge, GW; Soule, SE; Sun, SL	1
Fang, X; Sha, X	1
Gilbert, BE; Huaringa, A; Knight, V; Loyer, E; Newman, RA; Verschraegen, CF; Walsh, G	1
Baron, B; Chollet, P; de Jonge, MJ; de Wit, R; Droz, JP; Fumoleau, P; Lacombe, D; Mettinger, K; Paz-Ares, L; van Oosterom, AT	1
Baron, B; Daugaard, G; de Jonge, MJ; Fiedler, W; Fumoleau, P; Lacombe, D; Monfardini, S; Punt, CJ	1
Anderson, K; Atkinson, J; Bandyopadhyay, A; Gilbert, BE; Kline, K; Knight, V; Lawson, KA; Sanders, BG; Simmons-Menchaca, M; Snyder, RM; Sun, LZ	1
Braastad, CD; Chatterjee, D; Darnowski, J; Goldman, M; Goodglick, L; Pantazis, P; Wyche, JH	1
Agarwala, SS; Belani, CP; Egorin, MJ; Fakih, M; Friedland, DM; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Troetschel, M; Trump, DL; Vozniak, M; Wong, MM; Zamboni, WC	1
Belani, CP; Egorin, MJ; Fakih, M; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Trump, DL; Walko, C; Zamboni, WC	1
Cao, ZS; Dejesus, A; Giovanella, B; Mendoza, J	1
Fang, XL; Sha, XY; Wu, YJ	1
Dadashzadeh, S; Derakhshandeh, K	1
Burris, HA; Gerstein, H; Harris, J; Mettinger, KL; Reynolds, R; Rivkin, S; Staddon, A; Wax, A	1
Berlin, J; Caillouette, C; Chakravarthy, B; Choy, H; Daniel Beauchamp, R; Lockhart, AC; Merchant, N; Rothenberg, M; Scott Pearson, A; Shyr, Y; Tedesco, KL; Wyman, K	1
Egorin, MJ; Eiseman, JL; Hamburger, DR; Jin, R; Joseph, E; Jung, LL; Ramanathan, RK; Strychor, S; Zamboni, WC	1
Baka, S; Danson, S; Hoogendam, I; Linton, K; Lorigan, P; Mettinger, K; Ranson, M; Thatcher, N	1
Berlin, JD	1
Chedid, S; Cristofanilli, M; Esteva, F; Frye, DK; Hortobagyi, G; Ibrahim, N; Mettinger, KL; Rivera, E; Valero, V	1
Eiseman, JL; Harrold, JM; Joseph, E; Parker, RS; Strychor, S; Zamboni, WC	1
Egorin, MJ; Goel, S; Iqbal, T; Mani, S; Parise, RA; Repinski, TV; Strychor, S; Zamboni, WC	1
Takimoto, CH	1
Chen, J; Chu, X; Guo, J; Ping, Q; Song, M	1
Clark, JW	1
Chen, J; Chu, XZ; Guo, JX; Liu, L; Ping, QN; Song, MM	1
Fang, XL; Li, JC; Sha, XY; Zhang, LJ	1
Davis, TA; Egorin, MJ; Jung, LL; King, CR; Mani, S; Marsh, S; Maruca, LJ; McLeod, HL; Parise, RA; Potter, DM; Ramanathan, RK; Strychor, S; Zamboni, WC	1
Auber, M; Cai, C; Kiefer, G; Matin, K; Patel, H; Potter, D; Ramanathan, RK; Schmotzer, A; Stoller, R; Zamboni, W	1
Chen, J; Chu, XZ; Guo, JX; Ping, QN; Song, MM	1
Antonia, S; Cantor, A; Fishman, M; Garrett, C; Gump, J; Lush, RM; Munster, PN; Rocha-Lima, C; Simon, GR; Sullivan, DM; Tetteh, L; Williams, C	1
Cortes, J; Faderl, S; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S; Pierce, S; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S	1
Archer, GE; Chewning, TA; Friedman, HS; McLendon, RE; Ochiai, H; Pernell, CT; Sampson, JH	1
Dadashzadeh, S; Derakhshandeh, K; Erfan, M	1
Cai, B; Chen, J; Guo, J; Liu, M; Ping, Q	2
Fang, XL; Wu, J; Xing, B; Xu, B; Zhang, LJ	1
Caponigro, F; Cartenì, G; Davis, WB; Droz, JP; Milano, A; Pollard, P	1
Egorin, MJ; Eiseman, JL; Joseph, E; Parise, RA; Strychor, S; Zamboni, WC	1
Fan, Y; Gao, J; Gu, Z; He, B; Ming, J; Zhang, X	1
Liu, XY; Lu, JL; Wang, JC; Zhang, Q; Zhang, X; Zhao, H; Zhao, SX; Zhou, SF	1
Gao, JM; Gu, ZW; He, B; Ming, J; Zhang, XD	1
Herzog, TJ; Wethington, SL; Wright, JD	1
Gounder, M; Gu, Z; Kudelka, AP; Lee, SJ; Li, JM; Loyer, E; Rubin, EH; Thalasila, A; Verschraegen, CF	1
Dadashzadeh, S; Derakhshandeh, K; Shirazi, FH	1
Gao, J; Gu, Z; Ming, J; Zhang, X	1
Feng, L; Gu, B; Han, X; Liu, J; Liu, M; Liu, Y; Lu, W; Xie, C; Zhan, C	1
Fang, X; Jiang, Y; Sha, X; Zhang, W	1
Dadashzadeh, S; Derakhshandeh, K; Saghiri, R; Soheili, M	1
Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z	1
Ravivarapu, H; Redkar, S	1
Chen, Y; Fang, X; Gu, J; Jiang, X; Jiang, Y; Law, K; Sha, X; Xin, H; Zhang, W	1
Chang, S; Chen, Z; Gu, Z; He, B; Lu, J; Nie, Y; Xie, L; Zheng, S; Zou, S	1
Cao, Z; Dejesus, A; Giovanella, B; Kozielski, A; Liu, X; Mendoza, J; Vardeman, D; Wang, Y; Zhan, CG	1
Patel, D; Rahman, S; Saha, SC; Savva, M	1
Cai, BC; Chen, J; Chen, ZP; Fang, F; Gong, F; Gu, W; Hu, RR; Luo, L; Tian, R; Yang, XX	1
Gu, Z; He, B; Lai, Y; Li, D; Liang, Y; Wang, G	1
Hamilton, G; Klameth, L; Rath, B; Thalhammer, T	1
Dong, J; Fu, Y; Gong, T; Lian, X; Lin, Q; Teng, Y; Zhang, J	1
Chen, J; Dong, J; Gu, W; Lu, S; Peng, P; Xiong, Z; Xu, F; Yang, X	1
Huang, Y; Jiang, Y; Liu, G; Wang, H	1
Han, L; Li, R; Qing, J; Qiu, M; Ru, G; Sheng, J; Wang, J	1
Cao, Z; Hu, Z; Kou, X; Shao, C; Wang, Y; Wang, Z; Yu, T; Zhang, Q; Zheng, J	1
Karapetian, M; Kulikova, N; Tsikarishvili, S; Zaalishvili, G	1
Lake, MAI; Lees, RA; Lycett, GJ; Mann, HJ; Partridge, FA; Poulton, BC; Sattelle, DB	1
Chen, Y; Pan, J; Qing, C; Sun, Y; Tian, Y; Zhang, Y; Zhou, H; Zhu, Q	1

Reviews

8 review(s) available for camptothecin and rubitecan

Article	Year
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan]. Bulletin du cancer, 1998, Volume: Spec No Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Macromolecular Substances; Mice; Molecular Structure; Neoplasm Proteins; Prodrugs; Structure-Activity Relationship; Topoisomerase I Inhibitors	1998
Pharmacology of camptothecin esters. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Propionates; Topoisomerase I Inhibitors	2000
Alternative administration of camptothecin analogues. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Routes; Enzyme Inhibitors; Humans; Irinotecan	2000
New drugs for patients with pancreatic cancer. Current opinion in oncology, 2002, Volume: 14, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Capecitabine; Deoxycytidine; Diphtheria Toxoid; Fluorouracil; Gastrins; History, 16th Century; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic	2002
Advanced pancreatic cancer: is there a role for combination therapy? Expert review of anticancer therapy, 2003, Volume: 3, Issue:5 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine Endopeptidases; Deoxycytidine; Fluorouracil; Gemcitabine; Genes, ras; Glutamates; Guanine; Humans; Multienzyme Complexes; Pancreatic Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Sesquiterpenes	2003
A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics. Antiviral research, 2004, Volume: 61, Issue:1 Topics: Anti-HIV Agents; Antimetabolites; Antineoplastic Agents; Apoptosis; Camptothecin; Cyclin-Dependent Kinases; Flavonoids; HIV; HIV Infections; Humans; Piperidines; Purines; Receptors, Estrogen; Roscovitine; Topoisomerase I Inhibitors; Virus Replication	2004
Rubitecan. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors	2006
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	2008

Trials

33 trial(s) available for camptothecin and rubitecan

Article	Year
Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Middle Aged	1996
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-cancer drugs, 1998, Volume: 9, Issue:1 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors	1998
A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. International journal of oncology, 1999, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Patient Selection; Quality of Life; Survival Analysis; Tomography, X-Ray Computed	1999
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anti-cancer drugs, 1999, Volume: 10, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Rate	1999
Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Neoplasms	2000
Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Adult; Aerosols; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged	2000
A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies	2001
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2002, Volume: 62, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured	2002
Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anti-cancer drugs, 2002, Volume: 13, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Skin Neoplasms; Treatment Outcome; Uveal Neoplasms	2002
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Eating; Female; Humans; Male; Middle Aged; Neoplasm Metastasis	2002
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:10 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Tomography, X-Ray Computed	2002
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome	2002
Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Camptothecin; Cross-Over Studies; Drug Administration Schedule; Humans; Metabolic Clearance Rate; Models, Statistical; Sampling Studies	2002
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer, 2003, Jan-01, Volume: 97, Issue:1 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms	2003
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer, 2003, Jun-01, Volume: 97, Issue:11 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Gastrointestinal Neoplasms; Humans; Leiomyosarcoma; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome	2003
A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer. Investigational new drugs, 2004, Volume: 22, Issue:1 Topics: Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Camptothecin; Female; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis	2004
Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Apr-01, Volume: 10, Issue:7 Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Time Factors; Topoisomerase Inhibitors	2004
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms; Urothelium	2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:9 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Failure	2004
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-01, Volume: 10, Issue:15 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors; Treatment Outcome	2004
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:6 Topics: Administration, Oral; Camptothecin; Drug Administration Schedule; Humans; Neoplasms	2004
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. The oncologist, 2005, Volume: 10, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis	2005
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2005, Volume: 76, Issue:1 Topics: Adenocarcinoma; Administration, Oral; Aged; Camptothecin; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage	2005
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis	2005
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Disease Progression; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome	2006
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Cross-Over Studies; Fasting; Female; Food; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms	2006
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Investigational new drugs, 2006, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Female; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Polymorphism, Single Nucleotide	2006
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. Investigational new drugs, 2006, Volume: 24, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Treatment Failure; Treatment Outcome	2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Molecular cancer therapeutics, 2006, Volume: 5, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome	2006
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer, 2006, Oct-01, Volume: 107, Issue:7 Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Topoisomerase I Inhibitors; Treatment Outcome	2006
Phase II study of rubitecan in recurrent or metastatic head and neck cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local	2008
Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin. Investigational new drugs, 2008, Volume: 26, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Cisplatin; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Remission Induction; Young Adult	2008
A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors	2011

Other Studies

100 other study(ies) available for camptothecin and rubitecan

Article	Year
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. Journal of medicinal chemistry, 1986, Volume: 29, Issue:11 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Leukemia L1210; Solubility; Structure-Activity Relationship	1986
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. Journal of medicinal chemistry, 1998, Jan-01, Volume: 41, Issue:1 Topics: Acylation; Alkylation; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Mice; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Transplantation, Heterologous	1998
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. European journal of medicinal chemistry, 2014, Aug-18, Volume: 83 Topics: Animals; Antineoplastic Agents; Biological Transport; Camptothecin; Cell Line, Tumor; Chemistry Techniques, Synthetic; Humans; Intestinal Mucosa; Permeability; Rats	2014
Induction of senescent cell-derived inhibitor of DNA synthesis gene, SDI1, in hepatoblastoma (HepG2) cells arrested in the G2-phase of the cell cycle by 9-nitrocamptothecin. Laboratory investigation; a journal of technical methods and pathology, 1995, Volume: 73, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53	1995
The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cells. European journal of haematology, 1995, Volume: 55, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Hematopoietic Stem Cells; Humans; Hydrogen-Ion Concentration; Serum Albumin; Tumor Cells, Cultured	1995
Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action. Leukemia research, 1995, Volume: 19, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; DNA, Neoplasm; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Leukemia; Male; Mice; Mice, Nude; Topoisomerase II Inhibitors	1995
Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin. European journal of haematology, 1994, Volume: 53, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Adhesion; Cell Differentiation; Cell Division; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance; Flow Cytometry; Humans; Leukemia; Male; Mice; Mice, Nude; Monocytes; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured	1994
Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anti-cancer drugs, 1994, Volume: 5, Issue:4 Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Division; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Leukemia, Experimental; Microscopy; Tumor Cells, Cultured	1994
Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. European journal of haematology, 1994, Volume: 53, Issue:4 Topics: Animals; Antineoplastic Agents; Blood Cells; Camptothecin; Cells, Cultured; Humans; Mice; Tumor Cells, Cultured	1994
Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer research, 1994, Jun-15, Volume: 54, Issue:12 Topics: Administration, Oral; Animals; Camptothecin; Dogs; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Mice; Mice, Nude; Species Specificity; Tissue Distribution	1994
Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. The Journal of biological chemistry, 1994, Jan-28, Volume: 269, Issue:4 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Camptothecin; Cell Line; Cell Nucleus; Cell Survival; Clone Cells; Codon; DNA Primers; DNA Topoisomerases, Type I; DNA, Complementary; Drug Resistance; Humans; Kinetics; Leukemia, Myeloid; Mice; Molecular Sequence Data; Molecular Weight; Point Mutation; Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Amino Acid; Tumor Cells, Cultured	1994
Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer research, 1994, Feb-01, Volume: 54, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Division; Drug Administration Schedule; Humans; Kinetics; Melanocytes; Melanoma; Mice; Mice, Nude; Tumor Cells, Cultured	1994
New perspectives in colon cancer chemotherapy. Diseases of the colon and rectum, 1994, Volume: 37, Issue:2 Suppl Topics: Animals; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplantation	1994
9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. European journal of haematology, 1993, Volume: 50, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Death; DNA, Neoplasm; Growth Inhibitors; Humans; In Vitro Techniques; Leukemia, Experimental; Leukemia, Myeloid; Mice; Mice, Nude; Neoplasm Transplantation; Tumor Cells, Cultured	1993
Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. International journal of cancer, 1993, Mar-12, Volume: 53, Issue:5 Topics: Animals; Camptothecin; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured	1993
Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer research, 1993, Apr-01, Volume: 53, Issue:7 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; In Vitro Techniques; Mice; Mice, Nude; Tumor Cells, Cultured	1993
Induction of apoptosis in malignant and camptothecin-resistant human cells. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Androgens; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Cycle Proteins; DNA Topoisomerases, Type I; Drug Interactions; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Suramin; Tumor Cells, Cultured	1996
Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer research, 1997, Nov-15, Volume: 57, Issue:22 Topics: Antineoplastic Agents; Camptothecin; Cell Nucleus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia; Phenotype; Point Mutation; RNA, Messenger; Tumor Cells, Cultured	1997
Establishment of human prostate tumor xenografts in nude mice and response to 9-nitrocamptothecin in vivo and in vitro does not correlate with the expression of various apoptosis-regulating proteins. Journal of experimental therapeutics & oncology, 1996, Volume: 1, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured	1996
Comparative disposition of the antineoplastic agent 9-nitrocampotothecin and the inactive isomer 12-nitro camptothecin in CASE-bearing nude mice: effect of route of administration on tissue distribution. Cancer chemotherapy and pharmacology, 1997, Volume: 41, Issue:1 Topics: Animals; Antineoplastic Agents, Phytogenic; Autoradiography; Camptothecin; Infusions, Intravenous; Injections, Intramuscular; Isomerism; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Tissue Distribution; Tritium	1997
9-Nitrocamptothecin inhibits tumor recrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone. AIDS research and human retroviruses, 1998, Jan-01, Volume: 14, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; HIV Infections; HIV-1; Humans; RNA, Messenger; RNA, Viral; T-Lymphocytes; Tumor Necrosis Factor-alpha; Up-Regulation; Virus Activation	1998
Altered sensitivities to anticancer and differentiation agents in etoposide-resistant human myeloid leukemia U-937 cells. Journal of hematotherapy, 1998, Volume: 7, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Differentiation; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Myeloid; Lymphotoxin-alpha; Mice; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	1998
Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-kappa B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells. Anti-cancer drugs, 1998, Volume: 9, Issue:8 Topics: Antineoplastic Agents; Camptothecin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Host Cell Factor C1; Humans; Hydrogen Peroxide; I-kappa B Proteins; Interleukin-1; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Octamer Transcription Factor-1; Receptors, Tumor Necrosis Factor; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transcription Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	1998
9-nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells. AIDS research and human retroviruses, 1999, Feb-10, Volume: 15, Issue:3 Topics: Anti-HIV Agents; Antineoplastic Agents; Camptothecin; Drug Resistance; HIV Infections; HIV-1; Humans; NF-kappa B; Tumor Cells, Cultured; U937 Cells; Virus Replication	1999
Propionate and butyrate esters of camptothecin and 9-nitrocamptothecin as antileukemia prodrugs in vitro. European journal of haematology, 1999, Volume: 62, Issue:4 Topics: Animals; Antineoplastic Agents; Biotransformation; Butyrates; Camptothecin; Cell Cycle; Cell Division; HL-60 Cells; Humans; Liver; Mice; Prodrugs; Propionates; Structure-Activity Relationship; U937 Cells	1999
Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cells. Anti-cancer drugs, 1999, Volume: 10, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Flow Cytometry; HL-60 Cells; Humans; Hyperthermia, Induced; Leukemia	1999
Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Carriers; Humans; Liposomes; Mice; Mice, Nude; Microscopy, Electron; Neoplasm Transplantation; Neoplasms; Particle Size	1999
Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer. International journal of radiation oncology, biology, physics, 2000, May-01, Volume: 47, Issue:2 Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Radiation-Sensitizing Agents; Radiobiology; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay	2000
Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics. Teratogenesis, carcinogenesis, and mutagenesis, 2000, Volume: 20, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Drug Screening Assays, Antitumor; Epirubicin; Humans; Leukemia P388; Lymphocytes; Melphalan; Mice; Sister Chromatid Exchange	2000
Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Transactions of the American Clinical and Climatological Association, 2000, Volume: 111 Topics: Aerosols; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron; Neoplasm Transplantation; Neoplasms, Experimental; Osteosarcoma; Particle Size; Transplantation, Heterologous	2000
9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Camptothecin; Drug Carriers; Female; Humans; Liposomes; Lung; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2000
Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro. Neoplasia (New York, N.Y.), 1999, Volume: 1, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Differentiation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Flow Cytometry; G2 Phase; Humans; Melanins; Melanoma; Mice; Mice, Nude; Tumor Cells, Cultured	1999
9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Aerosols; Animals; Antineoplastic Agents; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Microscopy, Electron; Osteosarcoma; Particle Size; Phosphatidylcholines; Xenograft Model Antitumor Assays	2000
Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chemistry, Pharmaceutical; Colonic Neoplasms; Delayed-Action Preparations; Drug Stability; Humans; Lactones; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Rats; Rats, Sprague-Dawley; Solubility; Tissue Distribution; Xenograft Model Antitumor Assays	2000
In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Tumor Cells, Cultured	2000
Combined radiation and 9-nitrocamptothecin (rubitecan) in the treatment of locally advanced pancreatic cancer. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Camptothecin; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays	2000
9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy. Journal of medical virology, 2001, Volume: 64, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Flow Cytometry; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lymphocytes; Reverse Transcriptase Inhibitors; Virus Replication	2001
Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer research, 2001, Oct-01, Volume: 61, Issue:19 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 7; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Down-Regulation; Enzyme Activation; Enzyme Precursors; Fas Ligand Protein; fas Receptor; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Glycoproteins; Prostatic Neoplasms; Transfection; Tumor Cells, Cultured	2001
Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). International journal of oncology, 2002, Volume: 20, Issue:1 Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dogs; Drug Administration Routes; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms, Experimental	2002
Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene therapy, 2002, Volume: 9, Issue:5 Topics: Aerosols; Animals; Antineoplastic Agents; Camptothecin; Combined Modality Therapy; Genes, p53; Genetic Therapy; Liposomes; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Survival Rate	2002
Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Statistics in medicine, 2002, Jul-15, Volume: 21, Issue:13 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Camptothecin; Carboplatin; Clinical Trials, Phase I as Topic; Computer Simulation; Dexamethasone; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Maximum Tolerated Dose; Monte Carlo Method; Paclitaxel; Taxoids; Zoledronic Acid	2002
Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Aug-05, Volume: 775, Issue:2 Topics: Camptothecin; Chromatography, High Pressure Liquid; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet	2002
9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhalation toxicology, 2002, Volume: 14, Issue:2 Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents; Blood Chemical Analysis; Body Weight; Camptothecin; Dogs; Female; Liposomes; Male; Nebulizers and Vaporizers; Organ Size; Toxicity Tests; Urinalysis	2002
Preclinical activity of an i.v. formulation of rubitecan in IDD-P against human solid tumor xenografts. Anti-cancer drugs, 2002, Volume: 13, Issue:9 Topics: Animals; Antineoplastic Agents; Camptothecin; Capsules; Drug Administration Schedule; Drug Delivery Systems; Humans; Injections, Intravenous; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Particle Size; Treatment Outcome; Tumor Cells, Cultured	2002
Structure-activity relationship of alkyl 9-nitrocamptothecin esters. Acta pharmacologica Sinica, 2003, Volume: 24, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Esters; HL-60 Cells; Humans; Mice; Mice, Nude; Molecular Structure; Prodrugs; Structure-Activity Relationship; U937 Cells; Xenograft Model Antitumor Assays	2003
Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats. Acta pharmacologica Sinica, 2003, Volume: 24, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Bile; Biological Availability; Camptothecin; Feces; Injections, Intravenous; Random Allocation; Rats; Rats, Wistar; Tissue Distribution; Urine	2003
Identification of the metabolites of 9-nitro-20(S)-camptothecin in rats. Drug metabolism and disposition: the biological fate of chemicals, 2003, Volume: 31, Issue:6 Topics: Animals; Bile; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Chromatography, Liquid; Feces; Injections, Intravenous; Magnetic Resonance Spectroscopy; Mass Spectrometry; Rats; Rats, Wistar	2003
[Determination of 9-nitrocamptothecin in rat plasma and tissues by high performance liquid chromatography]. Yao xue xue bao = Acta pharmaceutica Sinica, 2003, Volume: 38, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Female; Liver; Lung; Male; Rats; Rats, Wistar; Tissue Distribution	2003
[A symphony for the camptothecins]. Bulletin du cancer, 2003, Volume: 90, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan	2003
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer research, 2003, Jun-15, Volume: 63, Issue:12 Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Dogs; Drug Resistance, Neoplasm; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Recombinant Fusion Proteins; Selection, Genetic; Transfection; Tumor Cells, Cultured	2003
Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC. Anti-cancer drugs, 2003, Volume: 14, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Transformation, Neoplastic; Clone Cells; Female; Flow Cytometry; Genes, bcl-2; Humans; Ovarian Neoplasms; Tumor Cells, Cultured	2003
Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Oct-05, Volume: 795, Issue:2 Topics: Animals; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Dogs; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence	2003
Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, Jan-05, Volume: 799, Issue:1 Topics: Animals; Antineoplastic Agents; Biotransformation; Camptothecin; Cattle; Humans; Liver; Reference Standards; Reproducibility of Results	2004
Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. International journal of pharmaceutics, 2004, Mar-19, Volume: 272, Issue:1-2 Topics: Animals; Antineoplastic Agents; Biological Transport; Caco-2 Cells; Camptothecin; Cyclosporine; Duodenum; Humans; Hydrogen-Ion Concentration; Ileum; In Vitro Techniques; Intestinal Absorption; Intestinal Mucosa; Jejunum; Male; Models, Biological; Rats; Rats, Sprague-Dawley; Verapamil	2004
Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:5 Topics: Aerosols; alpha-Tocopherol; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Female; Lymphatic Metastasis; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Vitamin E	2004
Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta. International journal of oncology, 2004, Volume: 25, Issue:2 Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspases; Cloning, Molecular; Drug Resistance, Neoplasm; Gene Expression; Humans; Male; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transfection; Tumor Cells, Cultured	2004
Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000. Drugs in R&D, 2004, Volume: 5, Issue:5 Topics: Animals; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiviral Agents; Camptotheca; Camptothecin; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors	2004
Synthesis and anti-tumor activity of alkenyl camptothecin esters. Acta pharmacologica Sinica, 2005, Volume: 26, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Esters; Humans; Inhibitory Concentration 50; Mice; Molecular Structure; Neoplasm Transplantation	2005
[The in vitro kinetics of uptake, transport and efflux of 9-nitrocamptothecin in Caco-2 cell model]. Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:10 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Camptothecin; Cyclosporine; Humans; Hydrogen-Ion Concentration; Temperature; Verapamil	2004
Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, Apr-25, Volume: 818, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Drug Stability; Humans; Lactones; Reproducibility of Results; Sensitivity and Specificity	2005
Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jul-01, Volume: 11, Issue:13 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; HT29 Cells; Humans; Mice; Mice, SCID; Treatment Outcome; Xenograft Model Antitumor Assays	2005
Current and future strategies for treating metastatic pancreatic cancer. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:8 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Management; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome	2004
Control-relevant modeling of the antitumor effects of 9-nitrocamptothecin in SCID mice bearing HT29 human colon xenografts. Journal of pharmacokinetics and pharmacodynamics, 2005, Volume: 32, Issue:1 Topics: Algorithms; Animals; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Female; HT29 Cells; Humans; Mice; Mice, SCID; Models, Statistical; Neoplasm Transplantation	2005
Are there any better camptothecins than the ones we have? Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors	2003
Pharmacokinetics of lactone, carboxylate and total 9-nitrocamptothecin with different doses and administration routes in rats. Biopharmaceutics & drug disposition, 2006, Volume: 27, Issue:2 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Camptothecin; Carboxylic Acids; Injections, Intravenous; Lactones; Male; Rats; Rats, Sprague-Dawley	2006
[In vitro and in vivo stability of 9-nitrocamptothecin lactone form in rats]. Yao xue xue bao = Acta pharmaceutica Sinica, 2005, Volume: 40, Issue:10 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Drug Stability; Lactones; Male; Rats; Rats, Sprague-Dawley	2005
[9-nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo]. Yao xue xue bao = Acta pharmaceutica Sinica, 2005, Volume: 40, Issue:11 Topics: Animals; Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Female; Hexoses; Liver; Lung; Macrophages, Peritoneal; Mice; Nanoparticles; Particle Size; Phagocytosis; Phosphatidylcholines; Polyethylene Glycols; Tissue Distribution	2005
Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug development and industrial pharmacy, 2006, Volume: 32, Issue:6 Topics: Animals; Antineoplastic Agents; Camptothecin; Cholesterol; Drug Compounding; Feasibility Studies; Glycine max; Hydrogenation; Injections, Intravenous; Liposomes; Male; Particle Size; Phosphatidylcholines; Rats; Rats, Sprague-Dawley; Solubility	2006
Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. Neurologia medico-chirurgica, 2006, Volume: 46, Issue:10 Topics: Animals; Antineoplastic Agents; Camptothecin; Disease Models, Animal; Glioblastoma; Injections, Spinal; Meningitis; Rats; Rats, Nude	2006
Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2007, Volume: 66, Issue:1 Topics: Antineoplastic Agents; Biocompatible Materials; Calorimetry, Differential Scanning; Camptothecin; Drug Compounding; Drug Delivery Systems; Lactic Acid; Microscopy, Electron, Scanning; Models, Theoretical; Molecular Structure; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Research Design; Technology, Pharmaceutical; X-Ray Diffraction	2007
Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin in rats. International journal of pharmaceutics, 2007, Aug-01, Volume: 340, Issue:1-2 Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Injections, Intramuscular; Injections, Intravenous; Lactones; Male; Rats; Rats, Sprague-Dawley	2007
Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Pulmonary pharmacology & therapeutics, 2008, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Delayed-Action Preparations; Drug Administration Routes; Female; In Vitro Techniques; Liposomes; Lung; Male; Mice; Particle Size; Rats; Rats, Sprague-Dawley; Solubility; Tissue Distribution	2008
Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Docetaxel; Female; Humans; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Ovarian Neoplasms; Taxoids; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays	2008
Preparation and characterization of novel polymeric micelles for 9-nitro-20(S)-camptothecin delivery. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2008, Jul-03, Volume: 34, Issue:2-3 Topics: Antineoplastic Agents; Camptothecin; Dioxanes; Drug Carriers; Drug Compounding; Drug Stability; Electrochemistry; Excipients; Magnetic Resonance Spectroscopy; Micelles; Particle Size; Polyethylene Glycols; Polymers; Solubility; Thermodynamics	2008
Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2008, Volume: 69, Issue:3 Topics: Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Buffers; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Drug Delivery Systems; Emulsions; Humans; Hydrogen-Ion Concentration; Male; Mice; Mice, Nude; Particle Size; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays	2008
Controlled release of 9-nitro-20(S)-camptothecin from methoxy poly(ethylene glycol)-poly(D,L-lactide) micelles. Biomedical materials (Bristol, England), 2008, Volume: 3, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Diffusion; Drug Carriers; Materials Testing; Micelles; Polyesters; Polyethylene Glycols	2008
Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection. Drug development and industrial pharmacy, 2008, Volume: 34, Issue:8 Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Injections, Intravenous; Lactones; Liver; Male; Rats; Rats, Sprague-Dawley; Tissue Distribution	2008
9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats. Anti-cancer drugs, 2008, Volume: 19, Issue:8 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Cell Line, Tumor; Cell Survival; Humans; Injections, Intravenous; Lactones; Male; Nanoparticles; Rats; Rats, Wistar; Tetrazolium Salts; Thiazoles	2008
[Investigations on preparation and release behavior in vitro of 9-nitro camptothecin encapsulated micelles]. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2008, Volume: 25, Issue:6 Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Humans; Micelles; Nanoparticles; Particle Size; Polymers; Solubility	2008
9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. International journal of pharmaceutics, 2009, May-08, Volume: 372, Issue:1-2 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Drug Evaluation, Preclinical; Folic Acid; HeLa Cells; Humans; Micelles; Neoplasms; Polymers	2009
Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: in vitro and in vivo evaluation. International journal of pharmaceutics, 2010, Sep-15, Volume: 397, Issue:1-2 Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; Area Under Curve; beta-Cyclodextrins; Camptothecin; Drug Evaluation, Preclinical; Drug Stability; Freeze Drying; Half-Life; Hydrogen-Ion Concentration; Hydrolysis; Male; Rats; Rats, Sprague-Dawley; Solubility; Temperature	2010
Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients. International journal of nanomedicine, 2010, Aug-09, Volume: 5 Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Camptothecin; Chromatography, High Pressure Liquid; Drug Carriers; Drug Delivery Systems; Drug Stability; Humans; In Vitro Techniques; Lactic Acid; Microscopy, Electron, Scanning; Nanomedicine; Nanoparticles; Neoplasms; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; X-Ray Diffraction	2010
Expect the unexpected-screen your screens. Journal of pharmaceutical sciences, 2011, Volume: 100, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Drug Compounding	2011
Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation. International journal of pharmaceutics, 2011, Aug-30, Volume: 415, Issue:1-2 Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; beta-Cyclodextrins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Compounding; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred ICR; Sarcoma 180; Toxicity Tests, Chronic; Xenograft Model Antitumor Assays	2011
Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. PloS one, 2011, Volume: 6, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Stability; Female; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Liver Neoplasms; Mice; Solubility; Ultrasonics; Water; Xenograft Model Antitumor Assays	2011
Anticancer activity of new haloalkyl camptothecin esters against human cancer cell lines and human tumor xenografts grown in nude mice. Anti-cancer agents in medicinal chemistry, 2012, Volume: 12, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Esters; Humans; Mice; Mice, Nude; Models, Molecular; Neoplasms; Prodrugs; Transplantation, Heterologous	2012
Physicochemical characterization, solubilization, and stabilization of 9-nitrocamptothecin using pluronic block copolymers. Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:10 Topics: Camptothecin; Drug Stability; Hydrogen-Ion Concentration; Hydrolysis; Lactones; Micelles; Oxidation-Reduction; Poloxamer; Polymers; Solubility; Temperature; Thermodynamics; Water	2013
Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:4 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Hydrogen-Ion Concentration; Injections, Intravenous; Lactones; Mice; Mice, Inbred ICR; Sarcoma 180; Tissue Distribution; Toxicity Tests	2013
Polymeric micelles with small lipophilic moieties for drug delivery. Colloids and surfaces. B, Biointerfaces, 2014, Apr-01, Volume: 116 Topics: Antineoplastic Agents; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Micelles; Molecular Structure; Polymers; Structure-Activity Relationship	2014
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. Molecules (Basel, Switzerland), 2014, Feb-17, Volume: 19, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan	2014
Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation. International journal of pharmaceutics, 2014, Dec-30, Volume: 477, Issue:1-2 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Transport; Caco-2 Cells; Camptothecin; Cell Culture Techniques; Drug Carriers; Drug Compounding; Endocytosis; Gastrointestinal Tract; Humans; Male; Mice, Inbred ICR; Molecular Structure; Particle Size; Polyethylene Glycols; Polyvinyls; Rats, Sprague-Dawley; Sarcoma 180; Surface Properties	2014
Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor. International journal of pharmaceutics, 2015, Jul-25, Volume: 490, Issue:1-2 Topics: Animals; Antineoplastic Agents; Camptothecin; Cyclodextrins; Drug Carriers; Drug Delivery Systems; Drug Stability; Lactones; Liposomes; Mice; Mice, Inbred ICR; Neoplasms; Rats; Rats, Sprague-Dawley; Transferrin	2015
New polymorphs of 9-nitro-camptothecin prepared using a supercritical anti-solvent process. International journal of pharmaceutics, 2015, Dec-30, Volume: 496, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Particle Size; Solvents	2015
Effects of borneol on the pharmacokinetics of 9-nitrocamptothecin encapsulated in PLGA nanoparticles with different size via oral administration. Drug delivery, 2016, Volume: 23, Issue:9 Topics: Administration, Oral; Animals; Biological Availability; Camphanes; Camptothecin; Drug Carriers; Drug Delivery Systems; Emulsions; Intestinal Absorption; Lactic Acid; Male; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley	2016
The development and validation of an LC-MS/MS method for the quantification of CZ112, a prodrug of 9-Nitrocamptothecin in rat plasma. Journal of pharmaceutical and biomedical analysis, 2020, Feb-05, Volume: 179 Topics: Animals; Antineoplastic Agents; Biological Availability; Camptothecin; Chromatography, Liquid; Male; Prodrugs; Rats; Rats, Wistar; Tandem Mass Spectrometry	2020
PARP inhibition suppresses topoisomerase 1 poisoning induced Caspase-3 dependent cell death in zebrafish embryos. Biochemical and biophysical research communications, 2021, 04-23, Volume: 550 Topics: Animals; Apoptosis; Camptothecin; Caspase 3; DNA Topoisomerases, Type I; Drug Synergism; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Topoisomerase I Inhibitors; Zebrafish	2021
Actions of Camptothecin Derivatives on Larvae and Adults of the Arboviral Vector Molecules (Basel, Switzerland), 2021, Oct-15, Volume: 26, Issue:20 Topics: Aedes; Animals; Antiviral Agents; Camptothecin; Drug Discovery; Female; High-Throughput Screening Assays; Humans; Insecticide Resistance; Insecticides; Larva; Mosquito Vectors; Motor Activity; Pandemics; Topoisomerase I Inhibitors; Vector Borne Diseases; Virus Replication; Zika Virus	2021
9-Nitro-20(S)-carbonate-camptothecin (NCP4), a novel prodrug of 9-nitrocamptothecin (9-NC), exhibits potent chemotherapeutic efficacy and improved safety against hepatocarcinoma. European journal of pharmacology, 2022, May-15, Volume: 923 Topics: Animals; Antineoplastic Agents; Camptothecin; Carbonates; Carcinoma, Hepatocellular; Humans; Lactones; Liver Neoplasms; Mice; Prodrugs	2022